Beruflich Dokumente
Kultur Dokumente
II.
Patent ................................................................................................................................................ 2
III.
Labiofam ........................................................................................................................................... 2
IV.
V.
VI.
Summary .......................................................................................................................................... 5
(310) 279-5154
info@petlifepharma.com
www.petlifepharma.com
The information contained in this document is subject to national and International Copyright laws and is
the proprietary and exclusive property of PetLife Pharmaceuticals, except as otherwise indicated. No part
of this document, in whole or in part, may be reproduced, stored, transmitted, or used for design purposes
without the prior written permission of PetLife Pharmaceuticals. The information contained in this document
is subject to change without notice. The information in this document is provided for informational purposes
only. Privacy Information: This document may contain information of a sensitive nature. This information
should not be given to persons other than those who are involved with PetLife Pharmaceuticals, or who will
become involved during the lifecycle.
I.
II.
Patent
PetLife owns exclusive veterinary rights to Arthur Mikaelians patent which achieved a full
patent in 2012 for the bioactive peptide (Blue Scorpion Venom) and polarization
technology (Patent # US 8,097,284 B2). This unique patented polarization technique
escalates the highly positive charges in the extracellular membrane of main compounds
in Escozine For Pets. This gives them the ability to function as a transportation
mechanism; it also intensifies the binding preferences with malignant cells.
The Patented Mikaelian Polarization technology plays an essential role in potentiating the
Blue Scorpion Venom and delivering more active ingredients directly into cancerous cells
in comparison to non-polarized ingredients. This technology allows fewer compounds to
be used and allows large scale commercialization of the natural version.
PetLifes exclusively owned bioactive peptide (Blue Scorpion Venom) and polarization
technology for veterinary use is the base for a novel pharmacologically active compound
which is critical in numerous new generation essential drugs and Nutraceuticals for
veterinary use.
III.
Labiofam
The Cuban laboratory, Labiofam, has no registration, patent or completed scientific
research regarding Escozul to make an adequately supported presentation of this product
to a regulatory agency or, for that matter, to the public. Further, actual production quality
control for medication of ESCOZUL does not exist at this time. Labiofam has completely
stopped the production of Escozul and it has been replaced by Vidatox, which is a
homeopathic version which has been diluted 1:1,000. We have a spectrophotometer
analysis of Vidatox which shows no evidence of venom.
The website, www.escozul-cancer.com, contains useful technical and scientific
information regarding Escozul. However, it also simultaneously posts misleading
History of Escozine For Pets
2014
IV.
V.
PetLife note: The two certificates referenced directly contain information deemed
proprietary and are not included in this White Paper. Select prospective partners or investors
may be granted access to the certificates, for due diligence purposes, under NDA.
VI.
Summary
Dr. Mikaelian is currently the only scientist who has completed all research and the
development process and has attained the legal registration to commercialize the Blue
Scorpion venom based product. This patent and technology has been licensed to PetLife
Pharmaceuticals for commercialization.
Escozine For Pets is solely owned and commercialized by PetLife Pharmaceuticals.
PetLifes sister company, Medolife, owns and markets the human product, Escozine. The
product, Escozul, is not produced or sold by Medolife and neither Medolife nor PetLife
rely on this product in any way.